Neil Exter - 17 Jun 2022 Form 4 Insider Report for Decibel Therapeutics, Inc.

Reporting relationship: Director, 10%+ Owner
Issuer ticker: N/A
Reported as of: 17 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jun 2022, 18:45:25 UTC
Prior SEC filing: 17 Jun 2022
Next SEC filing: 30 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Elisabeth Leiderman, Attorney-in-Fact

Key filing fact

Neil Exter filed Form 4 for Decibel Therapeutics, Inc. on 21 Jun 2022.

Key facts

This page summarizes Neil Exter's Form 4 filing for Decibel Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jun 2022, 18:45.

Change

Previous filing in this sequence was filed on 17 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DBTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +10,000
Change %
Price: $0.000000
Shares after: 10,000
Date: 17 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $2.30
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted on June 17, 2022 for 10,000 shares. The shares underlying the option are scheduled to vest in full on the one year anniversary of the date of grant of the option (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the option), subject to the reporting person's continued service.